معرفی
Dr. Ayman Qasrawi is an Assistant Professor of Internal Medicine at the University of Kentucky. A board-certified hematologist-oncologist, he completed medical school at Hashemite University (2012), residency at the University of Missouri-Kansas City (2018), and a post-doctoral fellowship at the University of Kentucky (2021). His work directly supports UN Sustainable Development Goals in health and well-being, with a focus on equitable cancer care.
Dr. Qasrawi’s research portfolio centers on acute leukemias, myelodysplastic syndromes, stem-cell transplantation, and the genomic epidemiology of obesity-associated malignancies. He employs molecular diagnostics, real-world data, and AI-driven analytics to refine risk stratification and personalize therapy. His investigations explore:
- Molecular mechanisms underlying therapy resistance in AML and ALL.
- Impact of obesity on mutational landscapes and clinical outcomes.
- Optimization of allogeneic and autologous transplant regimens.
- Novel FLT3, CD123, and BCL-2 targeted therapies.
Across 2024–2025, his peer-reviewed output demonstrates a clear trend toward translational studies integrating genomics, clinical trial data, and population-based outcomes to advance leukemia therapeutics. Notable themes include comparative effectiveness of targeted agents (gilteritinib vs midostaurin), timing of transplant interventions, and safety evaluation of CAR-T and hypomethylating agents.
Scientific Awards & Honors: While specific named awards are not detailed in the provided text, Dr. Qasrawi’s role as Principal Investigator on multiple phase-2/3 industry-sponsored trials and his substantial citation record (h-index 7, 113 citations) underscore recognition within the hematology-oncology community.
Research Funding & Leadership: He currently leads or co-leads 11 active or recently funded projects totaling multi-million-dollar support from Daiichi-Sankyo, Novartis, Kura Oncology, Sanofi, and OncoVerity. These studies span randomized placebo-controlled trials of quizartinib, venetoclax combinations, CAR-T strategies in SLE, and novel FLT3 inhibitors.
Laboratory & Clinical Teams: Dr. Qasrawi directs clinical research efforts embedded within the University of Kentucky’s Markey Cancer Center, collaborating with interdisciplinary teams in pathology, bioinformatics, and translational therapeutics to accelerate discovery-to-bedside pipelines.
